Benjamin Hadida

Pharma skepticism towards microbiome therapeutics, driven by past clinical failures and difficulty distinguishing robust science, has delayed partnership engagement until Phase II data. This workshop outlines how to package mechanistic insight and early clinical evidence to meet pharma expectations and unlock earlier, higher-quality partnering conversations.

Workshop highlights:

• Structuring differentiated mechanism-of-action narratives using immune, metabolic, and microbial pathways to position programs in language that resonates with pharma decision-makers.
• Aligning early clinical study design with pharma-preferred endpoints and indications to generate signals that support future regulatory and commercial success
• Positioning Phase I, translational, and biomarker datasets strategically to maintain engagement and credibility despite limited late-stage outcome data availability
• Demonstrating scientific validation across heterogeneous microbiome approaches to clearly separate high-quality programs from lower-confidence competitors in crowded pipelines